Bisphosphonates and glucocorticoids: Effects on bone quality

Arthritis and Rheumatism

Volumn 56, Issue 11, 2007, Pages 3518-3522

  Lems, Willem F ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ALFACALCIDOL; BISPHOSPHONIC ACID DERIVATIVE; DEOXYPYRIDINOLINE; GLUCOCORTICOID; OSTEOCLAST DIFFERENTIATION FACTOR; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PLACEBO; PREDNISOLONE; PYRIDINOLINE; RALOXIFENE; RISEDRONIC ACID; STRONTIUM RANELATE;

BONE DENSITOMETRY; BONE STRENGTH; CORTICOSTEROID INDUCED OSTEOPOROSIS; CORTICOSTEROID THERAPY; DRUG CHOICE; DUAL ENERGY X RAY ABSORPTIOMETRY; EDITORIAL; HUMAN; NONHUMAN; PRIORITY JOURNAL; RISK FACTOR; RISK MANAGEMENT;

ANIMALS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; GLUCOCORTICOIDS; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL;

EID: 36049025201     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.22975     Document Type: Editorial

References (29)

1. Curtis JR, Saag KG. Prevention and treatment of glucocorticoid-induced osteoporosis. Curr Osteoporos Rep 2007;5:14-21.
2. Van Staa TP. The pathogenesis, epidemiology and management of glucocorticoid-induced osteoporosis [review]. Calcif Tissue Int 2006;79:129-37.
3. Balooch G, Yao W, Ager JW, Balooch M, Nalla RK, Porter AE, et al. The aminobisphosphonate risedronate, in the presence of glucocorticoids, preserves localized mineral and material properties of bone. Arthritis Rheum 2007;56:3727-38.
4. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996;312:1254-9.
5. Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk [review]. Lancet 2002;359:1929-36.
6. Cefalu CA. Is bone mineral density predictive of fracture risk reduction? [review]. Curr Med Res Opin 2004;20:341-9.
7. Felsenberg D, Boonen S. The bone quality framework: determinants of bone strength and their interrelationships, and implications for osteoporosis management [review]. Clin Ther 2005;27:1-11.
8. Seeman E, Delmas PD. Bone quality: the material and structural basis of bone strength and fragility [review]. N Engl J Med 2006;354:2250-61.
9. O'Brien CA, Jia D, Plotkin LI, Bellido T, Powers CC, Stewart SA, et al. Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and bone strength. Endocrinology 2004;145:1835-41.
10. Lems WF, Van Veen GJ, Gerrits MI, Jacobs JW, Houben HH, Van Rijn HJ, et al. Effect of low-dose prednisone on calcium and bone metabolism in healthy volunteers. Br J Rheumatol 1998;37:27-33.
11. Manologas S, Weinstein RS. New developments in the pathogenesis and treatment of steroid-induced osteoporosis. J Bone Miner Res 1999;14:1061-6.
12. Rubin MR, Bilezikian JP. The role of parathyroid hormone in the pathogenesis of glucocorticoid-induced osteoporosis: a re-examination of the evidence [review]. J Clin Endocrinol Metab 2002;87: 4033-41.
13. Jia D, O'Brien CA, Stewart SA, Manologas SC, Weinstein RS. Glucocorticoids act directly on osteoclasts to increase their life span and reduce bone density. Endocrinology 2006;147:5592-9.
14. Humphrey EL, Williams JH, Davie MW, Marshall MJ. Effects of dissociated glucocorticoids on OPG and RANKL. Bone 2006;38: 652-61.
15. Wallach S, Cohen S, Reid DM, Hughes RA, Hosking DJ, Laan RF, et al. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 2000;67:277-85.
16. Saag K, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemarc S, et al, for the Glucocorticoid-induced Osteoporosis Intervention Study Group. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 1998;339: 292-9.
17. Ringe JD, Dorst A, Faber H, Schacht E, Rahlfs VW. Superiority of alfacalcidol over plain vitamin D in the treatment of glucocorticoid-induced osteoporosis. Rheumatol Int 2004;24:63-70.
18. De Nijs RN, Jacobs JW, Lems WF, Laan RF, Algra A, Huisman AM, et al. Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. N Engl J Med 2006;355:675-84.
19. Lane NE, Sanchez S, Modin GW, Genat HK, Pierini E, Arnuad CD. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis: results of a randomized controlled clinical trial. J Clin Invest 1998;102:1627-33.
20. Chavassiuex PM, Arlot ME, Roux JP, Portero N, Daifotis A, Yates J, et al. Effects of alendronate on bone quality and remodeling in glucocorticoid-induced osteoporosis: a histomorphometric analysis of transiliac biopsies. J Bone Miner Res 2000;15:754-62.
21. Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2000;15:993-1000.
22. American College of Rheumatology Ad Hoc Committee on Glucocorticoid- induced Osteoporosis. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update [review]. Arthritis Rheum 2001;44:1496-503.
23. Geusens PP, de Nijs RN, Lems WF, Laan RF, Struijs A, van Staa TP, et al. Prevention of glucocorticoid osteoporosis: a consensus document of the Dutch Society for Rheumatology. Ann Rheum Dis 2004;63:324-5.
24. Solomon DH, Katz JN, Cabrai D, Patrick AR, Bukowski JF, Coblyn JS. Osteoporosis management in patients with rheumatoid arthritis: evidence for improvement. Arthritis Rheum 2006;55: 873-7.
25. Guzman-Clark JR, Fang MA, Sehl ME, Traylor L, Hahn TJ. Barriers in the management of glucocorticoid-induced osteoporosis. Arthritis Rheum 2007;57:140-6.
26. Jacobs JW, van Everdingen AA, Verstappen SM, Bijlsma JW. Followup radiographic data on patients with rheumatoid arthritis who participated in a two-year trial of prednisone therapy or placebo. Arthritis Rheum 2006;54:1422-8.
27. Lems WF, Lodder MC, Lips P, Bijlsma JW, Geusens P, Schrameijer N, et al. Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial. Osteoporos Int 2006;17: 716-23.
28. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005;52:3381-90.
29. Russell RG. Determinants of structure-function relationships among bisphosphonates. Bone 2007;40 Suppl 2:S21-5.